Ainos (AIMD)
NASDAQ:AIMD
Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$2.28
$0.28(14.00%)
At close: 4:00 PM EST
$2.28
$0.28(14.00%)
Day’s Range― - ―
52-Week Range$1.26 - $4.50
Previous CloseN/A
Volume448.92K
Average Volume (3M)78.00K
Market Cap
$12.79M
Enterprise Value$14.95M
Total Cash (Recent Filing)$2.84M
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding8,524,542
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue825.48
Enterprise Value/Gross Profit-3.14
Enterprise Value/Ebitda-1.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI Nose PlatformAinos’s AI Nose platform is a durable technological differentiator: a platform approach to VOC-based sensing can be applied across multiple diagnostic and monitoring indications, enabling product line expansion, reuse of core R&D, and potential licensing or partnerships that create multi-year revenue opportunities.
High Gross Margins On Periods With RevenueWhen revenue is present the company reports high gross margins, indicating favorable unit economics for the core sensing/diagnostic products; this supports meaningful operating leverage if sales scale, allowing incremental revenue to flow to profitability once fixed R&D and G&A are absorbed.
Positive Equity And Asset BaseAinos holds tangible assets and positive equity, providing a balance sheet cushion to support ongoing R&D, potential collaborations, or non-dilutive financing; this asset base also affords options for partnering, asset-backed financing, or acquisition of complementary capabilities over the medium term.
Bears Say
Minimal And Declining RevenueRevenue near zero and a steep YoY decline indicate weak commercial traction and a fragile revenue foundation. Absent a credible path to sustainable sales, fixed R&D and operating costs cannot be supported internally, increasing reliance on financing and undermining long-term viability.
Large Ongoing Losses And Deeply Negative MarginsPersistent multi-million dollar net losses reflect that operating costs far exceed current income. Over time sustained losses erode equity, limit strategic flexibility, and force management to prioritize cash preservation over growth investments unless operating margins improve materially.
Material Leverage And Ongoing Cash BurnElevated debt relative to a small equity base and persistent negative operating and free cash flow create financing risk for a loss-making biotech. This structural cash burn increases probability of dilution or costly refinancing and limits ability to pursue long-term development without securing external capital.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.50 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $12.79M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Aug 18, 2026 which is in 89 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on May 13, 2026. The company reported -$0.408 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.408.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 8,524,542 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.408 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.585%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
43.89% Insiders
0.37% Mutual Funds
0.19% Other Institutional Investors
55.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---